Results. Seventy adolescents with psychosis were admitted to adult psychiatric wards over the 2-year period. The age range was 13 -18 years. Of the patients 80.0% were male, 37.1% reported a positive family history of mental illness, 50.0% smoked nicotine and 61.4% reported cannabis use.
The most common diagnoses were schizophrenia (30.0%) and schizophreniform disorder (27.1%). Sixty (85.7%) of the patients had a trial on a first-generation antipsychotic and 10 (15.5%) were initiated on a second-generation antipsychotic de novo. The average length of stay in hospital was 27.8 days. Of the patients, 40% defaulted follow-up after discharge.
Conclusions. Schizophrenia was the most common diagnosis.
There were high rates of cannabis use. The adolescents were managed in general psychiatric wards. The majority of patients had a trial on first-generation antipsychotics. There was a high rate of defaulting the first outpatient appointment.
There is a need to develop specialised inpatient adolescent psychiatric facilities and services, as well as to address comorbid substance use and non-adherence to treatment. associations between variables with categorical outcomes, while analysis of variance (ANOVA) was used for quantitative normally distributed outcomes. A p-value of <0.05 was considered statistically significant.
Ethics approval was obtained from the Biomedical Research Ethics
Committee of the University of KwaZulu-Natal, and permission to conduct the study was given by the provincial Department of Health and the hospital.
Results
A total of 70 adolescents were admitted to adult psychiatric wards over the 2-year period.
Demographic profile
The age range was 13 -18 years, with a mean of 16.79 (standard deviation (SD) 1.273) years. Of the patients, 80.0% (56) were male; 84.3% (59) were black, 10% Indian and 5.7% coloured; 72.1% (49) were of the Christian faith; 72.6% (51) spoke isiZulu and 18.6% (13) spoke English as their first language; and 85.7% (60) were living at home with family, 10.0% (7) in institutions and 1 with a foster family, while 2 had no fixed abode at the time of admission. Of the patients, 27.9% (17/61) were born in the South African winter months of June, July and August. The dates of birth for 9 patients were not available.
Associated risk factors
A positive family history of mental illness was reported by 37.1% (26) of the patients; 50.0% (35) of the adolescents smoked nicotine, 61.4% (43) admitted to cannabis use and 41.4% (29) reported alcohol use, in the past or at the time of admission; and 47.1% (33) reported adverse psychosocial stressors currently or in the past. The most common stressor described was the loss of a significant caregiver.
Six (8.6%) of the sample were mentally retarded and 22 (31.4%) had a positive forensic history prior to admission, with charges varying from theft to assault to rape.
Clinical profile
Forty-five (64.3%) of the adolescents were admitted with a first episode of psychosis while 25 (35.7%) had a past history of psychosis. The data on the sub-cohort of adolescents presenting with a first episode of psychosis will be reported on separately. The most common diagnoses in the present study were schizophrenia (30%) and schizophreniform disorder (27.1%). A co-morbid Axis I diagnosis was made in 28.6% (20) patients, the most common being a substance-related disorder; 64.3% (45) had a co-morbid medical diagnosis on Axis III, the most common being epilepsy (8.5%).
The results of basic haematological tests performed were generally normal, as summarised in Table II. Thyroid function tests were performed in 32 patients and were abnormal in 3 (4.3% of the total), and of 32 results of serological tests for syphilis reported, 1 was abnormal.
Of the 70 patients 38 had computed tomography (CT) scans of the brain, and 7 of these scans revealed abnormalities. The abnormalities reported are summarised in Table III. HIV status was not known in 95.7% of patients. HIV results were only available for 3 of the 70 files audited, with 1 patient being HIV positive.
Management
All the patients were prescribed antipsychotics; 60 (85.7%) patients had a trial on a first-generation antipsychotic, and only 10 (14.5%) were initiated on a second-generation antipsychotic de novo. A benzodiazepine was required for sedation in 41 cases (58.6%), and 29 patients (41.4%) received anticholinergic medication at some stage during admission. One patient received electroconvulsive treatment.
While 85.7% of the patients were initiated on typical antipsychotics, 27 (45.8%) of the 59 patients who were discharged from the unit were discharged on atypical antipsychotics. Eleven patients were transferred to another psychiatric unit and their discharge data were not available.
The average length of stay in hospital was 27.8 days (SD 23.8), and 94.3% (66) of the patients were admitted as involuntary mental health care users. Of those patients who were to be followed up at the unit, 60% attended the first visit after discharge; 31.3% of patients were prescribed typical antipsychotics and 44.4% of patients on atypical antipsychotics defaulted treatment, but this difference was not clinically significant (p=0.492).
Associations
There were no statistically significant associations between any of the following variables: positive family psychiatric history and age of presentation, substance use history and age of presentation, articles There was no statistically significant correlation between length of hospital stay and duration of symptoms before admission.
Discussion
While psychotic disorders are considered rare in adolescents, they may severely affect development and long-term functioning.
Early identification and intervention are critical to improving outcome. This chart review suggests that a considerable number of adolescents presenting with psychosis required lengthy periods of inpatient care as involuntary mental health care users in adult psychiatric wards.
Demographic profile
In this study, there was a preponderance of male adolescents with psychosis. This was also borne out in the Canadian Child and Adolescent First Episode Psychosis study (CAFEPS). 10 The majority of adolescents in our study were black Africans. In a recent British study, adolescents from the black ethnic group were over-represented among those admitted with a diagnosis of psychotic disorder. 11 Ethnic and cultural factors may influence the clinical presentation, response to treatment and prognosis of schizophrenia. 12 
Risk factors
Risk factors for the development of psychosis are multi-factorial.
The interplay between biological factors such as genetic vulnerability (suggested by a positive family history of mental illness), substance use, epilepsy and psychosocial stressors is evident in our study findings. Specifically, we observed high rates of substance use, psychosocial stressors, mental retardation and positive family history of mental illness.
A positive family history of mental illness supports the theory of a genetic vulnerability for the development of psychosis. Although a number of genes have been associated with schizophrenia, the exact genetic mechanisms of schizophrenia are still unclear. 13 Van Os proposes that while genetic factors contribute to the schizophrenia phenotype, the higher concordance rate for schizophrenia in monozygotic twins compared with dizygotic twins may in part be due to their sharing the same early environmental risk factors.
14 In a recent study on childhood IQ and adult mental disorders, low
IQ was an antecedent of many psychiatric disorders including schizophrenia spectrum disorders. Low IQ is also considered predictive of persistence and co-morbidity. 15 While the evidence is conflicting, it has been suggested that infections in early life (especially fetal and early childhood infections) play a role in the causation of schizophrenia. Births in winter are postulated as a risk factor, as neurotropic infections may contribute to schizophrenia in some cases. 6 In a Third-World setting, many children are exposed to a variety of infections during their early developmental years, and the possible role of these infections in the development of schizophrenia in adolescents requires further study. A larger sample would be required to clarify the role of infections in our local population.
Our results suggest a high prevalence of self-reported substance use (including nicotine, cannabis and alcohol) and are consistent with the literature. Weiser et al. reported a 12.4% prevalence of self-reported drug abuse in adolescent males with behavioural disturbances who were later hospitalised for schizophrenia, as opposed to a 5.9% prevalence in adolescent males who were not hospitalised later. 16 In their study, this association was specific for schizophrenia and all non-affective psychotic disorders, and was independent of cognitive functioning, social functioning and the presence of a non-psychotic disorder in the Draft Board assessment by the Israeli military. 16 Rates of substance use are high in psychotic adolescents, and this may be an attempt to selfmedicate early symptoms. Alternatively, cannabis may precipitate the psychotic illness. The risk of developing psychosis is thought to increase with longer duration of exposure to cannabis, with adolescents at particular risk. The adolescent brain is vulnerable, as it is still developing. 18 Substance use and especially misuse has significant implications for the management, course and prognosis of psychosis.
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Clinical profile
The differential diagnosis in children and adolescents presenting with psychotic symptoms is broad and includes primary psychotic disorders such as schizophrenia and schizo-affective disorder, and psychotic mood disorders such as bipolar mood disorder and psychotic depression. 2 In the present study, primary psychotic disorders were the most common diagnosis and only 7 patients were diagnosed with a mood disorder. The diagnostic spread in the present study is reflective of this spectrum, and diagnoses may evolve over time.
Co-morbid psychiatric and medical disorders tend to correlate with a poorer outcome. Patients with severe mental illness have higher than expected prevalence rates of co-morbid general medical conditions, particularly metabolic and cardiovascular disease. They are also at increased risk of contracting HIV infections. Conversely, these and other medical disorders also increase the risk of developing mental disorders. 19 A clinically significant level of medical co-morbidity and psychotic disorder due to general medical disorder was detected in our study, reinforcing the need for comprehensive screening
The estimated HIV seroprevalence ranges from 5% to 20 % in patients with psychosis. 20 A study by Mashaphu and Mkize at a psychiatric institution in KwaZulu-Natal found a 23.8% HIV seroprevalence rate in adults with first-episode psychosis. 20 In the current study, HIV results were available for only 3 patients were found in females. 21 The Moreno study concluded that larger CSF and lower grey matter volumes in the frontal lobes may be a nonspecific vulnerability marker for psychosis in male adolescents. 21 In our study, 7 of the scans showed abnormalities.
Although some abnormalities were not sufficiently clinically significant to warrant any further intervention, neuro-imaging remains an important investigation to detect subtle intracranial abnormalities that may otherwise be missed.
There is evidence to suggest that patients with severe mental illness are at increased risk of developing abnormal glucose homeostasis independent of treatment with medication. 19 Studies have mainly focused on atypical antipsychotics, and there is relatively little information on first-generation antipsychotics. 19 In the present, study the patients tested had normal random blood glucose levels. Clinicians need to monitor closely for the development of metabolic syndrome. Protocols for screening and regular monitoring of weight, abdominal circumference, glucose, cholesterol and triglycerides in these young patients need to be implemented.
Management
Atypical antipsychotics are commonly considered the treatment of choice in children and adolescents based on assumptions of efficacy and tolerabilty. 22 In the state sector in South Africa, and antipsychotic, showed that 74% of subjects discontinued their treatment before the end of the trial (18 months). There was no significant difference between the drugs in time to discontinuation due to intolerable side-effects. 23 This was also borne out in our study in that there was no significant difference in the outpatient follow-up rate between patients on first-or second-generation antipsychotics. The high rate of discontinuation of treatment in the present study reiterates the need for psycho-education of patients and families and comprehensive case management that also addresses psychosocial issues. Unfortunately, psychosocial interventions require extensive resources, and while initial results have been promising, sustained efficacy has not been confirmed in later studies in psychotic patients. 24 Owing to scarce resources, psychosocial interventions for psychotic patients are often very limited or even neglected in our setting.
All the patients in our sample were admitted to adult psychiatric wards because of a lack of dedicated adolescent facilities. The hospital has since opened an adolescent inpatient unit. Boeing et al. confirmed the widely held clinical impression that there is a gap in adolescent inpatient care provision, with 80% of first admissions being admitted into adult wards. 25 Adolescents in adult wards pose numerous risks, ethical concerns and therapeutic limitations, and this shortcoming in mental health facilities needs to be addressed.
Limitations
The study was a retrospective chart review and relied on medical records for data collection. Omissions or inaccuracies in the records would compromise the results of the study. Nonetheless, this study provides a valuable 'snapshot' of psychosis in adolescents. The small sample size of 70 patients may account for our negative correlation results.
The site of the study is a tertiary-level psychiatric hospital, which presents a bias towards severity of symptoms or aggression, which are the main reasons for admission. However, the site does provide a fair representation of adolescents admitted with psychosis, as psychiatric services in the region are generally scarce and unevenly distributed.
Conclusion
Schizophrenia was the most common diagnosis, and there were high rates of cannabis use among the psychotic adolescents. Most of the patients were male and isiZulu-speaking. The adolescents were all managed in adult psychiatric wards, and the majority of patients were initiated on first-generation antipsychotics. A deficiency in HIV screening was noted, and a significant number of patients defaulted treatment. The study therefore suggests that adolescents presenting with psychosis are a vulnerable clinical group that has significant psychopathology and requires intensive and age-appropriate specialist management.
Comprehensive evaluation, which includes identifying and addressing risk factors and investigating the patient to exclude general medical conditions, should be considered part of routine care. There needs to be special focus on enhancing treatment adherence and addressing co-morbid substance use in order to improve long-term outcome. Atypical antipsychotics should be considered as first-line treatment in adolescents with psychosis where possible.
Child and adolescent psychiatric services need to be prioritised.
There is a need to promote mental health programmes for adolescents and specifically to provide in-and outpatient services for psychotic adolescents. The local demographic factors, associated risk factors and clinical profile and the availability of different treatment options should be considered in planning future services and local treatment guidelines.
This study has provided a descriptive review, and further research is required on the epidemiology, risk factors, clinical features, management and prognostic factors of psychosis in children and adolescents. Better understanding of the many complexities in adolescents with psychosis will translate into enhanced treatment outcomes.
